Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature

Erum Khan1,2 · Ashish K. Shrestha2 · Mark A. Colantonio3 · Richard N. Liberio3 · Shitiz Sriwastava3,4

Received: 28 July 2021 / Revised: 28 August 2021 / Accepted: 30 August 2021 / Published online: 5 September 2021
© Springer-Verlag GmbH Germany, part of Springer Nature 2021

Abstract
Objective To report a unique case and literature review of post COVID-19 vaccination associated transverse myelitis and with abnormal MRI findings.

Background Coronavirus disease have been reported to be associated with several neurological manifestations such as stroke, Guillain-Barré syndrome, meningoencephalitis amongst others. There are only a few reported cases of transverse myelitis with the novel coronavirus (n-CoV-2). Here, we identify a post COVID-19 vaccination patient diagnosed with acute transverse myelitis.

Method A retrospective chart review of a patient diagnosed with post SARS-CoV-2 vaccination acute transverse myelitis, and a review of literature of all the reported cases of other post vaccination and transverse myelitis, from December 1st, 2010 till July 15th, 2021, was performed.

Conclusion To our knowledge, this is the one of early reported case of transverse myelitis and with post SARS-CoV-2 vaccination, who responded well to plasmapheresis. Further studies would be recommended to identify the underlying correlation between COVID-19 vaccination and transverse myelitis.

Keywords COVID-19 · SARS-CoV-2 · Transverse myelitis · MRI spine · Post vaccination myelitis

Abbreviations
SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2
RT-PCR Reverse transcription polymerase chain
ATM Acute transverse myelitis
CSF Cerebrospinal fluid
CNS Central nervous system
AEFI Adverse event following immunization
VAERS Vaccine adverse event reporting system
MHRA Medicines and healthcare products regulatory agency
NMO Neuromyelitis optica
PLEX Plasmapheresis
IVMP Intravenous methylprednisolone
MRC Medical research council

Introduction
As the coronavirus (COVID-19) vaccines are being distributed around the world, we are witnessing the rise of Adverse Event following Immunization (AEFI). The Vaccine Adverse Event Reporting System (VAERS) of Centers for Disease Control (CDC) has reported AEFI related to Pfizer-BioNTech, Moderna and Johnson and Johnson’s COVID-19 vaccines, among which there are reported neurological complications ranging from facial palsy to stroke [1]. The predominant post-vaccination side effects are the nonspecific systemic symptoms, among which the neurological symptoms include dizziness, headache, pain, muscle spasms, myalgia and paresthesia. On some rare occasions, tremor, dysphonia, diplopia, tinnitus, seizures and reactivation of herpes zoster have been reported [2]. Other serious neurological manifestation such as stroke, Guillain-Barré syndrome, Bell’s palsy, transverse myelitis and acute...
disseminated encephalomyelitis were also reported in the VAERS database and Medicines and Healthcare products Regulatory Agency (MHRA) from UK, COVID-19 database [1, 3–5].

According to the analysis of the database by CDC in the first month of vaccination, there appear to be very little to no safety concerns along with respect to the causal link between these side effects and vaccination [6]. However, due to the passive surveillance, the VAERS database is subjected to reporting bias and may contain some errors. Considering the large-scale vaccination campaign and less prevalence of neurological conditions in the population, the post-vaccination neurological morbidity may be due to chance alone.

Transverse myelitis (TM) is a very uncommon condition, and rarer is the vaccine-associated TM. However, some studies have reported its occurrence following administration of other vaccines, including diphtheria, tetanus toxoids and pertussis vaccine [7], measles, mumps, and rubella (MMR) virus vaccine [8, 9], oral poliovirus vaccine [10], Japanese encephalitis virus vaccine [11], hepatitis B vaccine [12–14], yellow fever vaccine [15, 16], typhoid vaccine [17], rabies vaccine [18], and seasonal influenza virus vaccine [19–25]. In addition, only oral polio vaccine was found to have a pathogenic causal relationship while other vaccines showed a temporal relationship to TM due to a common denominator such as an adjuvant [26].

We report a case of transverse myelitis after COVID-19 vaccination. To better identify and differentiate temporal and causal associations, AEFI should be reported with a low threshold of vigilance. As our understanding grows on fronts of disease as well as the vaccine, we will be able to better prevent and cure such dreaded outcomes.

Case report

A 67-year-old patient with a significant medical history of coronary artery disease, chronic kidney disease, neuropathy and a previous colon rupture with colostomy received her first dose of the Moderna COVID-19 vaccine on May 11th, 2021. On day one post-inoculation, she experienced bilateral upper and lower extremity weakness right more than left. 5 days later, the patient presented to the Emergency Department (ED) with complaints of symptoms described above. She described her symptoms as if she were “melting in the floor like a puddle”. She also mentioned tingling in right lower extremity and difficulty in ambulating requiring assistance for walking. She denied any vision changes, difficulty in swallowing or speech, shortness of breath, chest pain, and loss of smell or taste sensation.

Initial workup revealed decreased hemoglobin 8.5 g/dL (12.0–15.5 g/dL), hematocrit 27% (normal 36–48%), platelet count 1,30,000 platelets/μL (150,000–450,000 platelets/μL), Calcium 8.4 mg/dL (8.6–10.3 mg/dL, total protein 5.8 g/dL (6–8.3 g/dL), albumin 3.2 g/dL (3.4–5.4 g/dL). Creatinine was elevated to 1.32 mg/dL (0.7–1.2 mg/dL) and D-dimer elevated to 1.28 (range < 0.5).

On arrival, she was lethargic, oriented, afebrile and vitals were stable. Physical examination demonstrated cranial nerves were intact, however, motor strength showed Medical Research Council (MRC) grade of 3/5 throughout right lower extremity and 4/5 in right upper extremity, rest of motor strength was 5/5 on MRC scale. Upper motor neuron signs were present in bilateral lower extremities with Grade 3 + reflex, positive bilateral Babinski reflex and marked loss of vibration up to the ankle. Proprioception and light touch sensation were intact.

The patient underwent a brain CT, which was unremarkable. Brain MRI revealed scattered patchy foci nonspecific for white matter signal change suggestive of chronic microvascular changes no acute infarction; MRI of the cervical spine revealed hyperintense lesions in the upper cervical spine and cord edema extending from C1-C3 with patchy post-contrast enhancement (Fig. 1). MRI T- spine showed no intramedullary cord signal changes. Other investigations to determine the causes were done.

Cerebrospinal fluid (CSF) study revealed cell count 2, glucose 77 mg/dl, serum glucose 125 mg/dl, CSF protein 56 mg/dl, oligoclonal bands 2 in CSF and 2 in serum, with 0 isolated bands, IgG index 0.48. CSF labs yielded negative results for gram stain, culture, Cryptococcus, HSV, and VDRL, CSF-RT PCR negative for SARS-CoV-2. CSF paraneoplastic panel, autoimmune panel, flow cytometry, cytology were within normal limits. Patient’s basic metabolic panel (BMP), lipid panel, LFTs, CK, HbA1C were within normal limits. Serum perinuclear staining antineutrophil cytoplasmic antibody (P-ANCA), ANA, myeloperoxidase antibodies, cytoplasmic-ANCA and proteinase 3 were also negative. TPO Ab and thyroglobulin Ab test were within the normal limit. Hepatitis B, RPR and HIV testing were negative. Serum MOG antibodies (Ab), HTLV I/II Ab, MTB PCR were all negative. CSF and serum NMO Anti-AQP4 Ab were negative. Overall, findings were compatible with inflammatory central nervous system disorder and the presentation was thought to be from post-vaccination myelitis.

The patient was treated with IV solumedrol (IVMP) 1 g daily for 3 days. Patient showed no improvement with IV solumedrol, so Plasmapheresis (PLEX) therapy were initiated on 5/20/2021 for a 5-day period. On day 5 post-admission, the patient regained some use of her right hand, along with improved upper extremity weakness and underwent physical therapy was discharged to rehabilitation facility.

The patient began to show improvement in edema and right upper extremity weakness to the point where she was able to perform fine-motor movement. At outside Hospital, she continued to show improvements with her

 Springer
paresthesia and weakness. On follow-up in outpatient clinic on 07/15/2021, patient was able to ambulate without walker, motor strength was 4/5 throughout the right lower extremity, rest on the MRC motor scale was 5/5. Reflexes were 2/4, all cranial nerves were intact and marked loss of vibration was present up to the ankle. To gauge the recovery, repeat MRI scan was done and was consistent with improvement with no abnormal enhancement and improvement of prior seen abnormal hyperintensities on repeat MRI Cervical spine (Fig. 2). Further studies like motor and sensory evoked potentials were not done since the motor and sensory recovery was evident in outpatient examinations.

**Discussion**

Transverse myelitis has been attributed to infectious, parainfectious, systemic autoimmune diseases, paraneoplastic, and ischemic diseases. Acute infectious transverse myelitis is usually caused by herpes simplex virus type 2, varicella-zoster virus (VZV), Epstein-Barr virus (EBV) or cytomegalovirus (CMV), flaviviruses and enteroviruses [27–31].

As the various infections mentioned above can trigger an immune response in our body, similarly, administration of vaccine can also induce the same response. When our immune system cannot distinguish between foreign antigens and host antigens, then it triggers autoimmunity which leads
to the destruction of host cells. It is most commonly associated with environmental factors such as infectious antigens. Therefore, vaccine such as live attenuated or recombinant, can also induce autoimmunity leading to transverse myelitis [32, 33]. The following mechanisms induce autoimmunity in a person:

- The most common mechanism is molecular mimicry between infectious antigens and self-antigens [34].
- The acceleration of an ongoing autoimmune process by local activation of antigen-presenting cells and over processing of antigens induced by foreign antigens [35].
- Polyclonal activation of B lymphocytes or bystander activation which enhances cytokine production and further induce the expansion of autoreactive T-cells [36, 37].

Acute transverse myelitis basically presents with a varied signs and symptoms of sensory, motor and autonomic dysfunction. Pathological changes in the spinal cord tract are seen on spinal imaging, as a result of focal inflammation. As this disorder can lead to debilitating effects and permanent disability, it is imperative to recognize it early and distinguish it from other neurological entities. The diagnosis of transverse myelitis involves characteristic clinical presentation of bilateral signs and symptoms with a clearly defined sensory level, in addition to evidence on neuroimaging, CSF and serologic studies [38, 39]. The inclusion criteria of transverse myelitis include the non-specific hyperintense lesion of the spinal cord and isolated grey matter involvement which makes the differential of demyelinating diseases less likely as MS affects short segments usually and concerns white matter [40, 41].

Our case was diagnosed with transverse myelitis and fulfill the diagnostic criteria based on Transverse Myelitis Consortium Working Group [38]. Due to the absence of multiple sclerosis-like lesion in brain and oligoclonal bands in CSF along with extensive spinal cord lesion, the diagnosis of multiple sclerosis was unlikely. The imaging studies were also negative for acute disseminated encephalomyelitis and vascular lesions. Even though LETM is correlated with neuromyelitis optica, due to the absence of optic neuritis and neuromyelitis optica-IgG antibodies in serum, the diagnostic criteria are not met. Infectious cause is also ruled out due to negative serology tests along with negative CSF bacterial, viral and fungal culture results. Laboratory evidences of vasculitis and connective tissue disease were also absent. As most of the possible causes were eliminated, the above-mentioned featured were attributed to post vaccination TM following SARS-CoV-2 vaccination.

The case shows close temporal association to COVID-19 vaccination with symptoms presenting and worsening within a week of first dose of Moderna Vaccine. The patient did not show any signs of COVID-19 infection before this presentation, neither were COVID-19 antibodies detected in the serum. The acute attack of transverse myelitis appeared within a week of COVID-19 vaccination, and deterioration occurred on the 12th day. This is consistent with previously reported post covid vaccine-related TM [42, 43]. National board in UK has received reports like 22 cases of myelitis following the Pfizer-BioNtech Vaccine and 72 cases after AstraZeneca [3–5]. Whereas the VAERS CDC database reported so far total of 9 cases of transverse myelitis [1]. The marked deterioration and recovery may be cause by the immune dysregulation triggered by the vaccination. Immune dysregulation may have triggered acute transverse myelitis which may be secondary to vaccination. Neurological manifestations of both the PNS and CNS like GBS, ADEM, and ATM have been reported as vaccine induce immune-mediated events.

In our brief literature review, we reviewed cases of post-vaccination cases of transverse myelitis (Refer to Table 1). Among the 20 cases reviewed, 19 met diagnostic criteria for acute transverse myelitis according to Transverse Myelitis Consortium Working Group [38] except a case of post hepatitis B vaccine myelitis reported by Trevisani F et.al [13]. The most common reported vaccine-related myelitis was due to influenza vaccine (H1N1) (7 out of 20 cases) [19–25] followed by myelitis due to hepatitis B vaccine (3 of the 20 cases) [12–14]. Other causes of vaccine-related transverse myelitis included COVID-19 (SARS-CoV-2) vaccine [42], Japanese B encephalitis [11], Measles, Mumps and Rubella (MMR), inactivated Rabies vaccine [18], Diphtheria, tetanus and acellular pertussis (DTaP) vaccine [7], typhoid Vi capsular polysaccharide vaccine [17], oral Polio vaccine (OPV) [10], Yellow fever [15, 16].

The predominant patient population affected were males (13 M, 7 F) with an average age of 45.3 years old with age range 7 months to 70 years. Common clinical presentations included paresthesia and sensory deficits of the lower limbs, urinary retention, paraplegia and hyperactive reflexes. MRI of this patient population revealed non-enhancing longitudinal hyperintensities and extending from the cervical spine to the thoracic spine [19–24] rest had short segment intramedullary spinal cord lesion, case by Joyce K et.al and Trevisani had normal MRI imaging [8, 13]. Predominant cerebral spinal fluid (CSF) analyses revealed normal white blood cells (WBC) and relatively normal glucose and elevated protein levels. Oligoclonal bands, NMO and MOG were either absent or not reported. Patients improved with IVMP and/or PLEX therapy. All of the 20 confirmed cases showed at least partial symptomatic improvement. Four cases had only partial improvement, while 16 had near complete resolution of symptoms. Based on the literature, IVMP ± IVIG may improve the clinical course in post-vaccination acute transverse myelitis (Refer Table 1).
| Author/country      | Age/gender | Type of vaccine                  | Time duration from vaccination to symptom onset | Clinical presentation                                                                 | Lab work, CSF, serological and immunologic markers                                                                 | MRI findings                                                                                           | Managements | Outcomes | Based on proposed diagnostic criteria of acute transverse myelitis fulfill or not full diagnostic criteria |
|--------------------|------------|----------------------------------|------------------------------------------------|---------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|--------------|----------|---------------------------------------------------------------|
| Akkad W et. al./USA| 27/F       | Nasal novel influenza (H1N1) vaccine | < 1 week                                       | Back pain and lower extremity weakness. Paresthesia of legs, urinary retention and inability to stand | CSF: WBC - 517/mm³, Protein - 223 mg/dl, Glucose - 41 mg/dl. No oligoclonal bands, NMO NA, MOG NA | MRI spine-intramedullary hyperintensity extending from the cervical medullary junction throughout the length of the thoracic cord, no enhancement | IVMP, PLEX   | Improved | Fulfilled                                                      |
| Bakshi R. et. al./USA | 36/F     | Influenza (H1N1) vaccine           | 4 weeks                                        | Leg weakness and numbness below chest with associated urinary retention                  | CSF: WBC - 84, Protein - 96 mg/dl, Glucose - normal. Elevated myelin basic protein. NMO NA, MOG NA | MRI cervical and thoracic spine - diffuse hyperintensity from C1-C3 to the visualized upper thoracic levels along with with no enhancement | IVMP         | Improved | Fulfilled                                                      |
| Pagenkopf C. et. al./Germany | 45/M     | COVID-19 (SARS-CoV-2) vaccine      | > 1 week                                       | Chills, headache, thoracic back pain and generalized weakness. Acute flaccid tetraparesis | CSF: WBC - 481/mm³, Protein - 140 mg/dl, Glucose - 43 mg/dl. No oligoclonal bands, NMO NA, MOG NA | MRI spine- T2 hyperintense signal of the spinal cord from C3 to T2 without gadolinium enhancement | IVMP         | Improved | Fulfilled                                                      |
| Author/country (country) | Age/gender | Type of vaccine | Time duration from vaccination to symptom onset | Clinical presentation | Lab work, CSF: serological and immunologic markers | MRI findings | Managements | Outcomes | Based on proposed diagnostic criteria of acute transverse myelitis fulfillment or not full diagnostic criteria |
|-------------------------|------------|-----------------|-----------------------------------------------|-----------------------|---------------------------------------------------------------------------------|--------------|-------------|----------|--------------------------------------------------|
| Matsui M. et. al. (Japan) | 4/F | Japanese B encephalitis (JBE) vaccine | 2 weeks | Pain in knees and lumbar spine. Lower limb weakness, progressive flaccid paraplegia and areflexia | CSF: WBC- 950/mm3, Protein-62 mg/dl, Glucose- 45 mg/dl No oligoclonal band. NMO NA, MOG NA | MRI spine high signal intensity on T2-weighted imaging between T6-T7 and L2 MRI brain normal | IVIG | Partially improved | Fulfilled |
| Joyce K et. al. (UK) | 20/M | MMR vaccine | 2 weeks | Urinary retention and ascending paresthesia. Flaccid paraplegia | CSF: WBC- 370/mm3, Protein-180 mg/dl, Glucose- 54 mg/dl NMO NA, MOG NA | MRI brain and spinal cord normal | IV steroid | Partially improved | Fulfilled |
| Fonseca L. et. al. (Brazil) | 3/M | Hepatitis B vaccination (HBV) | < 1 week | Urinary retention and lower limb weakness | CSF: WBC- 2/mm3, Protein-25 mg/dl, Glucose- 82 mg/dl NMO NA, MOG NA | MRI spine hyperintense signal from C4 to T3 | IVMP IVIG | Improved | Fulfilled |
| Trevisani F. et. al. (Italy) | 11/F | Hepatitis B vaccine (HBV) | 3 weeks | Back pain, leg weakness and urinary retention. Flaccid paraplegia | CSF: WBC- NA Protein- increased Glucose- NA NMO NA, MOG NA | MRI brain and spinal cord normal | NA | Improved | Not Fulfilled |
| Song H. et. al. (South Korea) | 31/M | Hepatitis B vaccine (HBV) | 2 weeks | Paresthesia in upper and lower extremities | CSF: within normal limits, absent oligoclonal bands and myelin basic protein. NA NMO NA, MOG NA | MRI cervicothoracic spine-T2 high signal at C4 to C5 cord level with isolated enhancement in posterior column between C4 and C5 cords Brain MRI normal | IVMP | Improved | Fulfilled |
| Author/country | Age/gender | Type of vaccine | Time duration from vaccination to symptom onset | Clinical presentation | Lab work, CSF, serological and immunologic markers | MRI findings | Managements | Outcomes | Based on *proposed diagnostic criteria of acute transverse myelitis fulfill or not full diagnostic criteria |
|---------------|------------|----------------|-----------------------------------------------|-----------------------|--------------------------------------------------|--------------|-------------|----------|-----------------------------------------------|
| Larner A et. al. (UK) | 42/M | Nasal novel influenza (H1N1) vaccine | > 1 week | Difficulty walking and right-sided weakness | CSF: Normal limit, no oligoclonal bands | MRI spine showed hyper-intensity of the cervical portion of the spinal cord with hazy ill-defined enhancement of the upper cervical cord following gadolinium | IVMP | Improved | Fulfilled |
| Bir L et. al. (Turkey) | 25/M | Inactivated Rabies Vaccine (Rabipur) | 8 weeks | Back pain with lower limb weakness and urinary/bowel retention | CSF: WBC-110/mm³, Protein-114 mg/dl, Glucose-70 mg/dl, No oligoclonal bands | MRI spine-hyperintense lesion and expansion at the level of conus medullaris | IVMP Azathioprine | Improved | Fulfilled |
| Nakamura N. et. al. (Japan) | 70/M | Influenza Vaccination (HA type, 22–7-B) | < 1 week | Upper limb paraplegia, paresis and hyperactive patellar reflexes. Absent sensation below T5. Back ache and dysuria | CSF- within normal limit | MRI spine – High T2 signal intensity in C6-T3 vertebral level | IVMP PLEX IVIG | Improved | Fulfilled |
| Riel-Romero R et. al. (USA) | 7 Month/M | Diphtheria, tetanus, acellular pertussis (DTaP) | > 2 weeks | Urinary dribbling and priapism. Lower extremity weakness and flaccid paraplegia | CSF: WBC-7 l/mm³, Protein-30 mg/dl, Glucose-63 mg/dl, no oligoclonal bands | MRI of the spinal cord showed diffuse T2 signal within the spinal cord from the level of C3–T6 with a faint and patchy enhancement | IVMP | Partially improved | Fulfilled |
| Author/country          | Age/gender | Type of vaccine                                      | Time duration from vaccination to symptom onset | Clinical presentation                                                                                   | Lab work, CSF, serological and immunologic markers | MRI findings                                                                 | Managements | Outcomes   | Based on *proposed diagnostic criteria of acute transverse myelitis fulfill or not full diagnostic criteria |
|------------------------|------------|------------------------------------------------------|-----------------------------------------------|--------------------------------------------------------------------------------------------------------|---------------------------------------------------|--------------------------------------------------------------------------------|--------------|------------|----------------------------------------------------------|
| Das R et. al. (Nepal)  | 19/M       | Typhoid Vi capsular polysaccharide vaccine (ViCPS)   | < 1 week                                      | Complete sensory loss from lower abdomen to both legs. Symmetrical weakness of both legs and spastic paraplegia, urine overflow and dribbling | CSF: WBC-5 / mm³, Protein-80 mg/dl, Glucose-44 mg/dl. No oligoclonal bands. NA NMO NA, MOG NA | MRI spine— high intensity signal in the T2 weighted signal extending over several spinal segments at T12-L4 level | IVMP         | Improved   | Fulfilled                                                |
| Lim S et. al. (South Korea) | 9/F       | Measles, Mumps and Rubella vaccine (MMR)            | > 2 weeks                                    | Urinary retention, low back pain and lower limb weakness                                           | CSF: WBC-0 / mm³, Protein-48 mg/dl, Glucose-96 mg/dl. Increased myelin basic protein. NA NMO NA, MOG NA | MRI cervical and thoracic spine— extensive intramedullary high signal intensities in the entire cervical and thoracic spinal cords (C-2 to T-10) without gadolinium enhancement | IVMP         | Improved   | Fulfilled                                                |
| Vieira M. et. al. (Brazil) | 52/F      | Trivalent Influenza (H1N1) vaccine                  | 1 week                                       | Acute urinary hesitancy and constipation. Spastic asymmetric paraparesis                           | CSF: within normal limit. NA NMO NA, MOG NA                                                   | MRI spine— T2 hyperintense lesion the spinal cord at T4                               | NA           | NA         | Fulfilled                                                |
| Kozic D. et. al. (Serbia) | 7/M       | Oral polio vaccine (OPV)                            | > 2 weeks                                    | Fever and associated ataxia. Progressive muscle pain and weakness                                | CSF: WBC-30 / mm³, Protein-normal, Glucose-normal NA NMO NA, MOG NA                           | MRI Cervical spine— diffusely increased T2W signal from C2-C6 without enhancement. MRI1 brain- normal | IVIG, Steroid | Improved   | Fulfilled                                                |
Table 1 (continued)

| Author/country          | Age/gender | Type of vaccine   | Time duration from vaccination to symptom onset | Clinical presentation                                                                                                                                                                                                 | Lab work, CSF, serological and immunologic markers | MRI findings                                                                                       | Managements  | Outcomes   | Based on *proposed diagnostic criteria of acute transverse myelitis fulfill or not full diagnostic criteria |
|-------------------------|------------|-------------------|-----------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|-----------------------------------------------------------------------------------------------|--------------|------------|---------------------------------------------------------------|
| Bartol K. et. al. (USA) | 35/M       | Yellow Fever      | 1 week                                        | Urinary retention and associated sensory disturbances and weakness in extremities. Decreased strength in lower extremities. Ascending paresthesia to elbows and knees.                                          | CSF: WBC- 300 / mm³, Protein- 147 mg/dl, IgM antibody positive for Yellow Fever.NA NMO NA, MOG NA | MRI spine- longitudinally extensive signal abnormality in the spinal cord extending from the cervical-medullary junction into the thoracic spinal cord | IV Steroids, PLEX | Improved  | Fulfilled                                                                                       |
| Gui L et. al. (China)   | 13/M       | Influenza (H1N1)  | < 1 week                                      | Bilateral motor and sensory impairment in lower extremities. Flaccid paraplegia with retention of urine and feces.                                                                                                | CSF: WBC- 10 / mm³, Protein- 28 mg/dl, Glucose- NA NMO NA, MOG NA | MRI spine-hyperintensity in the spinal cord from C4 to T6 | IVMP          | Improved  | Fulfilled                                                                                       |
| Sato N et. al. (Japan)  | 77/F       | Influenza (H1N1)  | < 1 week                                      | Tetraplegia and impaired sensation below spinal C5. Diminished                                                                                                                                      | CSF: WBC- 2/ mm³, Protein- 36 mg/dl, Glucose- NA, IL-6 increased, no oligoclonal band NA NMO NA, MOG NA | MRI spine- longitudinally extensive intramedullary lesion from the C2 level down to the upper thoracic spine with gadolinium enhancement in the lesion at the C3-4 level | IVIG, IVMP | Partially improved | Fulfilled                                                                                       |
These reports may not be able to identify causality as no distinction can be made between infectious and other etiology. However, a higher vigilance may provide further insights of the disease, its pathophysiology and vaccination implications. This may be determined whether any association is the cause of the higher frequency of TM observed post vaccination. It may be required to undergo risk-benefit analysis to determine the continuation of vaccination. However, as of now, vaccination seem to outweigh the risks, and a full-fledged vaccination campaign should be continued.

**Conclusion**

As the neurologic impact of the COVID-19 pandemic keeps growing, vaccine-related disorders are coming to our notice. Certainly, diligent reporting is needed for a better judgment of the actual relevance and potential risk. We will need to perform a detailed risk-benefit analysis to determine the course of action concerning vaccines if such events increase in significance. The rarity of such an occurrence should currently not deter the use of vaccines, since global vaccination represents the most important strategy to fight this pandemic.

**Acknowledgements** West Virginia Clinical and Translational Science Institute, Morgantown, WV; SS supported in part by WVCTSI via US National Institute of General Medical Sciences of National Institute of Health under award under 5U54GM104942-05.

**Author contributions** Conceptualization: SS. Drafting the manuscript: EK, AKS, MAC, RL, SS. Editing and final draft: SS.

**Declarations**

**Conflicts of interest** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Ethical approval** Patient consent available, IRB approval from West Virginia University protocol Id 200498561.

**Informed consent** Informed consent from the patient was also obtained.

**Consent for publication** Available and IRB approved.

**References**

1. Human USDoHa, Services (DHHS) PHSP, Centers for Disease Control (CDC)/Food and Drug Administration (FDA) VAERS, (VAERS) 1990-07/09/2021 CWO-ID. Vaccine adverse event reporting system (VAERS). http://wonder.cdc.gov/vaers.html. Accessed 25 July 2021
2. Possible side effects after getting a COVID-19 vaccine. [https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html). Accessed 25 July 2021

3. COVID-19 mRNA Pfizer-BioNTech vaccine analysis print. Medicines and healthcare products regulatory agency (MHRA) COVID-19 mRNA Pfizer-BionNTech vaccine analysis print. [https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/summary-public-assessment-report-for-pfizerbiontech-covid-19-vaccine](https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/summary-public-assessment-report-for-pfizerbiontech-covid-19-vaccine).

4. COVID-19 Moderna vaccine analysis print. Medicines and healthcare products regulatory agency (MHRA) COVID-19 mRNA Moderna vaccine analysis print. [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1005198/COVID-19-vaccine_Moderna_analysis_print.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1005198/COVID-19-vaccine_Moderna_analysis_print.pdf). Accessed 25 July 2021

5. COVID-19 vaccine AstraZeneca analysis print. Medicines and healthcare products regulatory agency (MHRA) COVID-19 mRNA AstraZeneca vaccine analysis print. [https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjOpPmMr-PyAhXQTN8KHdVBCWQfFnoECAMQAAw&usg=AM957wK3OnF17C1nPlK7FzN7UswvF-MQc](https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjOpPmMr-PyAhXQTN8KHdVBCWQfFnoECAMQAAw&usg=AM957wK3OnF17C1nPlK7FzN7UswvF-MQc).

6. Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, Nair N, Martin S, Clark T, Markowitz L, Lindsey N, Zhang B, Licata C, Jazwa A, Sotir M, Shimabukuro T (2021) First month of COVID-19 vaccine safety monitoring—United States, December 14, 2020–January 13, 2021. MMWR Morb Mortal Wkly Rep 70(8):283–288. [https://doi.org/10.15585/mmwr.mm7008e3](https://doi.org/10.15585/mmwr.mm7008e3) (PMID: 33630816).

7. Riel-Romero RM (2006) Acute transverse myelitis in a 7-month-old boy after diphtheria-tetanus-pertussis immunization. Spinal Cord 44(11):688–691. [https://doi.org/10.1038/sj.sc.3101879](https://doi.org/10.1038/sj.sc.3101879) Epub 2009 Nov 29, Erratum in: Spinal Cord, 2007 Jun;45(6):463. PMID: 16317420.

8. Joyce KA, Rees JE (1995) Transverse myelitis after measles, mumps, and rubella vaccination. BMJ 311(7002):422. [https://doi.org/10.1136/bmj.311.7002.422a](https://doi.org/10.1136/bmj.311.7002.422a) (PMID: 76405491).

9. Lim S, Park SM, Choi HS, Kim HB, Yang BG, Lee JK (2003) Transverse myelitis after measles and rubella vaccination. BMJ 311(7002):422. [https://doi.org/10.1136/bmj.311.7002.422a](https://doi.org/10.1136/bmj.311.7002.422a) (PMID: 76405491).

10. Bartol KD, Aguirre JL, Labruzzo SV, Henriot RP (2019) Transverse myelitis associated with yellow fever vaccination. Proc (Bayl Univ Med Cent) 32(2):283–285. [https://doi.org/10.1002/pmc6.1573405](https://doi.org/10.1002/pmc6.1573405) (PMID: 31191156;PMCID:PMC6541067).

11. Akkad W, Salem B, Freeman JW, Huntington MK (2010) Longitudinal extensive transverse myelitis following vaccination with nasal attenuated novel influenza A(H1N1) vaccine. Arch Neurol 67(10):1018–1020. [https://doi.org/10.1100/archneurol.2010.167](https://doi.org/10.1100/archneurol.2010.167) (PMID: 20697056).

12. Nakamura N, Nomura S, Katsuta T, Koga H, Tachi M, Terada M, Kato H, Itoh Y, Osawa H, Ozeki T, Yamamoto H (2003) Neurologic complications associated with influenza vaccination: two adult cases. Intern Med 42(2):191–194. [https://doi.org/10.2169/internalmedicine.42.191](https://doi.org/10.2169/internalmedicine.42.191) (PMID: 12636241).

13. Moeckli R, Mazzotta JC (1996) Acute transverse myelitis after influenza vaccination: magnetic resonance imaging findings. J Neuroimaging 6(4):248–250. [https://doi.org/10.1111/j.1109-2704.1996.tb00648.x](https://doi.org/10.1111/j.1109-2704.1996.tb00648.x) (PMID: 8903080).

14. Bir LS, Esmerli FO, Cenikli U, Erdogan C,Degirmenci E (2007) Transverse myelitis following hepatitis B vaccination. J Hepatol 19(2):317–320. [https://doi.org/10.1136/jh30000200009](https://doi.org/10.1136/jh30000200009) (PMID: 17288305; PMCID: PMC1940283).

15. Longitudinal myelitis associated with yellow fever vaccination. J Spinal Cord Med 30(3):294–296. [https://doi.org/10.1079/JSPM2007.11753940](https://doi.org/10.1079/JSPM2007.11753940) (PMID:17684898;PMCID:PMC2031962).

16. Cortes JM, Llera RM, Saez MI, Fernandez E, Llombart MA, Gonzalez E (2010) Acute transverse myelitis following typhoid vaccination. Ulster Med J 76(1):39–40. [https://doi.org/10.1016/j.ulstermedj.2009.11.003](https://doi.org/10.1016/j.ulstermedj.2009.11.003) (PMID: 19579072).

17. Das RN, Jaykumar J (2007) Acute transverse myelitis following typhoid vaccination. Ulster Med J 76(1):39–40. [https://doi.org/10.1016/j.ulstermedj.2009.11.003](https://doi.org/10.1016/j.ulstermedj.2009.11.003) (PMID: 19579072).

18. Aslan A, Kurugol Z, Gokben S (2014) Acute transverse myelitis at the conus medullaris level after rabies vaccination in a patient with Behçet’s disease. J Spinal Cord Med 30(3):294–296. [https://doi.org/10.1079/JSPM2007.11753940](https://doi.org/10.1079/JSPM2007.11753940) (PMID:17684898;PMCID:PMC2031962).

19. Sato N, Watanabe K, Ohta K, Tanaka H (2011) Acute transverse myelitis and acute motor axonal neuropathy developed after vaccination against seasonal and 2009 A/H1N1 influenza. Intern Med 50(5):503–507. [https://doi.org/10.2169/internalmedicine.50.1430](https://doi.org/10.2169/internalmedicine.50.1430) (Epub 2011 Mar 1 PMID: 21372468).

20. Longitudinal extensive transverse myelitis following vaccination with nasal attenuated novel influenza A(H1N1) vaccine. Arch Neurol 67(10):1018–1020. [https://doi.org/10.1001/archneurol.2010.167](https://doi.org/10.1001/archneurol.2010.167) (PMID: 20697056).

21. Caldas C, Bernicker E, Nogare AD, Luby JP (1994) Case report: transverse myelitis associated with Epstein-Barr virus infection. Am J Med Sci 307(1):45–48. [https://doi.org/10.1097/00000441-199401000-00009](https://doi.org/10.1097/00000441-199401000-00009) (PMID: 8291507).
30. Minami K, Tsuda Y, Maeda H, Yanagawa T, Izumi G, Yoshikawa N (2004) Acute transverse myelitis caused by Coxsackie virus B5 infection. J Paediatr Child Health 40(1–2):66–68. https://doi.org/10.1111/j.1440-1754.2004.00295.x (PMID: 14718010)
31. Martinovic V, Kisic-Tepavecovic D, Kacar A, Mesaros S, Pekmezovic T, Drulovic J (2019) Longitudinally extensive transverse myelitis in a patient infected with West Nile virus. Mult Scler Relat Disord 32:19–22. https://doi.org/10.1016/j.msard.2019.04.007 (Epub 2019 Apr 16 PMID: 31005826)
32. Agmon-Levin N, Kivity S, Szyper-Kravitz M, Shoenfeld Y (2009) Transverse myelitis and vaccines: a multi-analysis. Lupus 18(13):1198–1204. https://doi.org/10.1177/0961203309345730 (PMID: 19880568)
33. Tishler M, Shoenfeld Y (2004) Vaccination may be associated with autoimmune diseases. Isr Med Assoc J 6(7):430–432 (PMID: 15274537)
34. Blank M, Barzilai O, Shoenfeld Y (2007) Molecular mimicry and autoimmunity. Clin Rev Allergy Immunol 32(1):111–118. https://doi.org/10.1007/BF02686087 (PMID: 17426366)
35. Lehmann PV, Forsthuber T, Miller A, Sercarz EE (1992) Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358(6382):155–157. https://doi.org/10.1038/358155a0 (PMID: 1373768)
36. Barzilai O, Ram M, Shoenfeld Y (2007) Viral infection can induce the production of autoantibodies. Curr Opin Rheumatol 19(6):636–643. https://doi.org/10.1097/BOR.0b013e3282f0ad25 (PMID: 17917546)
37. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, Miller JD, Slansky J, Ahmed R (1998) Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8(2):177–187. https://doi.org/10.1016/s1074-7613(00)80470-7 (PMID: 9491999)
38. (2002) Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 59(4):499–505. https://doi.org/10.1212/wnl.59.4.499 (PMID: 12236201)
39. Jacob A, Weinschenker BG (2008) An approach to the diagnosis of acute transverse myelitis. Semin Neurol 28(1):105–120. https://doi.org/10.1055/s-2007-1019132 (PMID: 18256991)
40. Kitley JL, Leite M, George JS, Palace JA (2012) The differential diagnosis of longitudinally extensive transverse myelitis. Mult Scler 18(3):271–285. https://doi.org/10.1177/1352458511406165 (Epub 2011 Jun 13 PMID: 2166935)
41. Bot JC, Barkhof F, Polman CH, Lycklama à Nijeholt GI, de Groot V, Bergers E, Ader HJ, Castelijns JA (2004) Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 62(2):226–233. https://doi.org/10.1212/wnl.62.2.226 (PMID: 14745058)
42. Pagenkopf C, Südmeyer M (2021) A case of longitudinally extensive transverse myelitis following vaccination against Covid-19. J Neuroimmunol 358:577606. https://doi.org/10.1016/j.jneuroim.2021.577606 (Epub ahead of print. PMID: 34182207; PMCID: PMC8223023)
43. Singh Malhotra H, Gupta P, Prabhu V, Garg RK, Dandu H, Agarwal V (2021) COVID-19 vaccination-associated myelitis. QJM. https://doi.org/10.1093/qjmed/hcab069 (Epub ahead of print. PMID: 33787891; PMCID: PMC8083508)